The exact role of calcitonin (CT) in the pathogenesis of postmenopausal osteoporosis remains unknown. Whole plasma calcitonin (iCT) basal levels, metabolic clearance rate (MCR), and production rate (PR) of CT were measured in 9 premenopausal and 16 postmenopausal women, including 11 osteoporotics (OP). Basal iCT levels were statistically lower in postmenopausal women than in the premenopausal group (P < 0.01) and strongly correlated (r = 0.72; P < 0.001) with estrone circulating levels (El). MCR were similar in all groups. PR were similar in eugonadal women between 22 (mean±SD = 30.9±9.9 tg/d) and 37 yr (mean±SD = 25.5±11.1 ,ug/d) premenopausal women. In healthy postmenopausal women PR were reduced, but not significantly (mean±SD = 19.5±6.95 pg/d), whereas osteoporotic patients presented a highly significant reduction of CT PR (mean±SD = 9.8±4 gg/d) (P < 0.01). Because there is a strong relationship between El and PR (r = 0.64; P < 0.001), CT secretory capacity appears to be modulated by estrogen circulating levels. This modulation leads to a menopause-related decrease in iCT. In osteoporotics, an independent impairment of CT production drastically lowers PR and basal iCT levels. CT might be one of the determining factors in the pathogenesis of postmenopausal osteoporosis.
Introduction
Calcitonin (CT)' has been known for many years to inhibit osteoclastic resorption of bone (1, 2) . Therefore, CT is frequently used for treatment of metabolic bone diseases characterized by increased bone turnover (3) . Recently, CT has been 1 . Abbreviations used in this paper: CT, calcitonin; CV, coefficient of variation; El, estrone; iCT, whole plasma immunoreactive calcitonin; MCR, metabolic clearance rate; OP, osteoporosis; PR, production rate. shown to reduce postmenopausal bone loss (4) and to potentially restore decreased bone mass (5) .
However, notwithstanding the therapeutic effect of CT on bone diseases, the exact role of CT in the pathogenesis of postmenopausal osteoporosis (OP) remains controversial. CT concentrations have been reported to be lower in women than in men, regardless of the assay method (6, 7) . Some investigators have suggested that calcitonin secretion may decline at the menopause (8) and be stimulated by estrogen (9) , although this is not yet generally accepted (10) . A decreased immunoreactive calcitonin response to calcium infusions has also been described in postmenopausal osteoporotic women, suggesting that calcitonin deficiency may be involved in the development of postmenopausal osteoporosis (11) .
In this study, we investigated the relationship between age or menopause with CT secretory capacity and the influence of plasma estrone (El) levels on CT secretory capacity. We also investigated whether osteoporotic patients have absolute or relative CT deficiency.
Methods
Patients. 24 female subjects completed the entire experimental procedure. Informed consent was obtained from all subjects before the trial, which had the prior approval of the Local Ethical Committee.
Subjects were divided into four groups. Group I consisted of five subjects aged [19] [20] [21] [22] [23] Statistical analysis. Data were normalized using a log-transformation for statistical analysis. Groups were compared using analysis of variance (ANOVA) and individual differences were assessed by means ofsimultaneous confidence intervals. This methodology made possible the analysis of small-sized samples like group III. As indicated previously, patient' data regarding follicular and luteal phases were not different and were therefore merged so as to increase the sample size. We verified that ANOVA performed on all six groups (with follicular and luteal phases considered separately in groups I and II) or in four groups (follicular and luteal phases of groups I and II pooled) yielded identical conclusions.
A linear regression analysis was performed to investigate the relationship between plasma El, age, CT plasma basal levels, and CT production rates (15). 
Results
All basal plasma iCT determinations were within the detection limit of the assay (> 15 pg/ml) and stay within the normal range for our lab (< 120 pg/ml) ( Table I) . Mean basal levels were not statistically different between group I (mean±SD = 84.2±18.4 pg/ml) and group II (mean±SD = 74.2±24.7 pg/ml) or between group III (mean±SD = 47.5±19.5 pg/ml) and group IV (mean±SD = 32.3±9.8 pg/ml) (Fig. 1) . Using the ANOVA analysis, iCT basal levels in groups I and II were statistically higher than that of groups III and IV. No significant correlation was found between the age of the subjects and basal plasma iCT in the two groups of premenopausal women or in the groups constituted by postmenopausal subjects or in the entire population.
Calculated MCR in groups I (mean±SD = 366±77.5 liter/ 24 h), II (mean±SD = 335.7±62.3 liter/24 h), III (mean±SD = 420±67 liter/24 h), and IV (mean±SD = 298.9±32.6 liter/ 24 h) were not significantly different (Fig. 1) . ,gg/24 h), and III (mean±SD = 19.5±6.95 ,ug/24 h), whereas values obtained in group IV (mean±SD = 9.8±4 ,ug/24 h) were significantly decreased (Fig. 1 ). Linear regression relationship did not show any statistically significant difference between age of the subjects and PR of CT in any of the two groups of premenopausal women or in the groups constituted by postmenopausal subjects or in the whole population.
Plasma El levels were measured during 27 out of 33 procedures performed in 24 subjects. Plasma estrone levels were not significantly different in groups I (mean±SD = 99.3±41.8 ng/liter) and II (mean±SD = 92.1±31.7 ng/liter) but groups I and II were significantly higher than group III (mean±SD = 36±21 ng/liter) and group IV (mean±SD = 32.2±12.9 ng/ liter) in which all values were within the same range (Fig. 1) .
Linear regression analysis showed a significant correlation both between basal levels of iCT and E values (r = 0.73 and P < 0.001) (Fig. 2) and between PR of CT and plasma El (r = 0.64 and P < 0.001) (Fig. 3) . i. 60 i0 20 
Discussion
Several discrepancies about the validity of whole plasma CT determinations currently exist between authors. CT circulates in the plasma in heterogeneous forms (16, 17) and whole CT assays cross-react with several fragments of larger molecular weight than native monomeric CT (18) . As it is possible, but not proved, that some of these immunoreactive CT forms do not possess biological activity, whole CT assays might overestimate the fraction of plasma calcitonin with biological activity. However, it is still unclear whether fragments of lower or higher molecular weight than monomeric 1-32 calcitonin are completely deprived of inhibiting activity on osteoclasts. In this study we use an assay for iCT with high sensitivity, characterized by a lower limit of detection (< 15 pg/ml) and a maximal normal value of 120 pg/ml. With such an assay, no subject was found to have undetectable basal plasma iCT and all results for basal iCT were within the normal range.
Confficting data exist on the respective effects of age or menopause on basal iCT levels (7, 8) . Several authors (19, 20) . found that women had lower iCT concentrations than men. In our study, premenopausal women did not show any decrease in basal iCT between 22 and 37 yr, but after menopause, basal iCT levels are significantly decreased independent of the existence of osteoporosis. Our values of CT MCR are slightly lower than described by previous reports. Assuming a mean weight of 65 kg for females, previous data reported MCR values of -750 liters/24 h for subjects <30 yr old and 550 liters/24 h for subjects > 50 yr old, using the iCT assay (7) . In this study, the changes in MCR throughout life were not statistically modified by menopause or age. This is consistent with our findings presented here. In our osteoporotic group, the mean values were not statistically different from those obtained in healthy women.
Few estimates of the CT production rates are available in human subjects. Using the same rate of monomeric CT infusion (20,ug/kg), Kanis et al. (13) found PR of CT three to four times higher than that found in our healthy population. Their assay gave undetectable results in 20% of normal subjects and a maximum normal value of 980 pg/ml, which may lead to a greater overestimation of CT circulating levels than does the assay used in our study. Tiegs et al. (7), using an assay with properties more similar to ours, described normal female subjects as having PR This study is the first report of measurement of CT PR in a population of osteoporotic women. Group IV shows production rates of CT drastically reduced. This decrease is significant with respect to groups I, II, and III. Values of CT PR in group IV are reduced to one third of production rates of calcitonin measured in young healthy females and to one half of those reported in healthy age-matched postmenopausal women. These results are in conflict with the measurements of basal calcitonin (10) or calcitonin secretory reserve (21) previously reported to be normal or high in postmenopausal osteoporosis.
Plasma El levels reflect the menopausal status of our subjects. The values of El are high in eugonadal women. We expect plasma El to be high reflecting normal ovarian function, because we excluded women with irregular menstruations or previous history of gynecological dysfunction. Our experimental procedures were performed on days 12 and 22 of the menstrual cycle corresponding to late follicular and luteal phases, respectively, in which basal plasma El levels are reported to be high and within the same range (22) . Low values of plasma El found in our postmenopausal groups were not surprising because these women (mean age: 68 yr) had been postmenopausal for several years. This elapsed time span in menopause results in the disappearance of high E 1 levels due to a remanent ovarian secretion, as commonly seen during the first years of menopause. Plasma El values reported here in postmenopausal women are probably related to peripheral aromatization of circulating androgens, specifically androstenedione, produced by adrenal glands, into estrone (23) .
In our population, there was a direct relationship (P < 0.001) between basal E l levels and basal iCT levels as well as CT PR suggesting an influence of estrogenic secretion on calcitonin metabolism. This confirms previous studies (8) showing that deficiency in serum estrogen is associated with a decrease in serum basal iCT.
Because no age-related decrease appeared in eugonadal women or in postmenopausal women, our data, support the findings ofTiegs et al. (7) and suggest that age by itselfdoes not play a major determinant influence on iCT secretory capacity, at least within groups in which El levels remain in the same range.
E l levels are not statistically different in groups III and IV but CT production rates are collapsed in group IV. It may be assumed that this fall of secretory capacity of CT in osteoporotic patients involves not only a menopause-related phenomenon, like group III, but also a specific pathway that does not occur in healthy women. Because group IV has also the lowest CT MCR, this specific impairment of CT metabolism cannot be related to an excessive catabolism ofthe hormone but, more likely, to a defect in CT production or secretion.
In conclusion, in an eugonadal women population, as long as El circulating levels remain high, no evidence appears that CT secretory capacity might be decreased by an age-related mechanism. But in our two groups of postmenopausal women, healthy or osteoporotic, there was a fall in plasma circulating El levels leading through a menopause-related effect to a reduction of CT secretory capacity. This reduction of CT secretion, whereas MCR remain constant, leads to a reduction in iCT basal levels in postmenopausal women compared with premenopausal women. Furthermore, because osteoporotic patients presented a highly significant reduction of CT production rates even when compared with healthy patients matched for age and El levels, it is probably that in addition to the menopause-related effect, this reduction of CT secretory capacity in osteoporotics has to be related to a specific and still unknown impairment of CT metabolism.
These findings describe for the first time CT secretory capacity in an osteoporotic population. These results provide a better understanding of the role of CT in the pathogenesis of postmenopausal osteoporosis and help to consider prevention and treatment of osteoporosis by CT not only as a pharmacological but also as a etiopathogenic therapy.
